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OBJECTIVE: To evaluate functioning and resource use
of schizophrenic patients treated with antipsychotic
agents. METHODS: One thousand eight hundred forty-
seven schizophrenic out-patients who initiated or altered
antipsychotic treatment were studied for one year. Four
consultations were made at baseline, 3, 6, and 12 months
intervals. Health care resource use for schizophrenia
treatment was recorded as well as the Social Functioning
Scale (SFS): Social Relations (SR), Interpersonal Commu-
nication (IC) and Independence (I). There were two
cohorts: patients who started Olanzapine, (1091, 59.1%)
and patients on other antipsychotics, (756, 40.9%, of
which 187 were on Quetiapine, 471 on Risperidone and
98 on typical antipsychotics). RESULTS: Sixty-four
percent of subjects were male, mean age 38.9 (13) and
58.1% under 40. 20.3% were employed and 39.4%
unemployed. First presentation for schizophrenia was
made at approximately 28 (10) years, of which 28.7%
had attempted suicide on one occasion. At baseline visit,
76.4% were on antipsychotics and, in the previous six
months, had been hospitalised for schizophrenia related
treatment for an average of 10.7 (23) days, attended a
day-centre 9.7 (27) times and had seen a psychiatrist 10
(15) times. Both groups experienced improvements in
Social Functioning: the Olanzapine group had increased
scores of 10.2 (16.6), 11.6 (19.7), and 7.5 (18.6) in terms
of SR, IC and I, while the other group observed increases
of 7.1 (16.4), 7.5 (18.6), and 5.4 (17.5), respectively. No
differences were detected between cohorts in terms of
service use: 17.9% of patients attended a day-centre on
average 8.7 times and 99.9% of patients saw a psychia-
trist, an average of 9.7 visits per patient annually. There
were slight differences (p < 0.01) in the number of 
hospitalisations (11.2%: Olanzapine group and 14.8%:
other antipsychotics) but no difference in duration of 
stay (2.7 days per annum). CONCLUSIONS: Function-
ing of schizophrenic patients improved in terms of 
social relations, interpersonal communication and 
independence.
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OBJECTIVE: To investigate the real pharmacoutilization
of antidepressant drugs in primary care. METHODS: An
observational cohort study was conducted among all
population (356,000 inhabitants) listed in the adminis-
trative databases of the Local Health Unit of Ravenna. 
In a time horizon of 5 years (1996–2000), all patients
exposed to antidepressant drugs were included. Pharma-
ceutical and nosocomial databases were cross-linked to
evaluate drugs used, concomitant diseases, and hospital-
izations. Pharmacoutilization proﬁle was deﬁned accord-
ing to the number of renewed prescriptions per year, and
categorized as continual, non-continual or occasional
exposure. RESULTS: A cohort of 27,139 patients was ret-
rospectively evaluated. Part of them (n = 5,989, 22.1%),
received a variable treatment combination including 
heterocyclic or selective serotonin re-uptake inhibitors
(SSRIs) or other drugs. With reference to monotherapy,
39.1% of patients (n = 10,612) were exposed to hetero-
cyclic, 31.5% (n = 8,548) to different drugs as 5-
hydroxytryptamine-antagonists, monoamine oxidase
inhibitors, or others, and 7.3% to SSRIs (n = 1,990).
Among evaluated patients, 18.6% [n = 5,044; mean age
63 ± 17yrs; 65% female] were exposed to a continual
treatment, 23.1% [n = 6,271; mean age 61 ± 18yrs; 69%
female] to a non-continual treatment, and 58.3% [n =
15,824; mean age 54 ± 20yrs; 63% female] to an occa-
sional treatment. Interestingly, in patients on occasional
treatment both the lowest mean age and percentage of
female were registered. Compared with all other groups,
in patients with a continual exposure was observed the
lowest statistically signiﬁcant frequency of patients
treated with heterocyclic (21.8%; p < 0.001) and the
highest percentages of those with SSRIs (12.0%; p <
0.001). In the group on continual treatment (54.7%),
concomitant cardiovascular diseases were signiﬁcantly
higher in comparison with those on different treatment
proﬁles (p < 0.001), suggesting in this case a more aware-
ness in the treatment of depression. CONCLUSION:
Results from population-wide databases show 7.6% of
patients were exposed to antidepressant drugs; however,
just a small proportion of them (18.6%) were on a con-
tinual exposure.
